Münster, Germany, 9 December 2019, Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that Frontiers Immunology, the international, peer-reviewed, open-access, online publication journal, has published an article entitled:
Recombinant haemagglutinin derived from the ciliated protozoan Tetrahymena thermophila is protective against Influenza infection.